Participate in Research

Browse Clinical Trials
Clinical Trial for People with Huntington’s Disease
Protocol: STUDY00006857
Full Title
718-CIH-301: A PHASE 3, MULTICENTER, OPEN-LABEL SAFETY STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF SAGE-718 IN PARTICIPANTS WITH HUNTINGTON DISEASE
Description
The University at Buffalo (UB) Department of Neurology is conducting a study for people with Huntington’s Disease (HD). The goal of the study is to see if the study drug (SAGE-718) is safe and effective to treat people with HD.

Participants will be enrolled in the study for up to one year. They will take a pill containing the study drug by mouth every morning. They will also complete physical exams and surveys throughout the study. Participants will be paid for their time and effort.
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
Adults 25 to 65 years old Have been diagnosed with Huntington's Disease
Age Group: Adults
Principal Investigator: Kelly Andrzejewski
Contact(s)
Sarah Thomas
sathomas@buffalo.edu
+1 716-382-1808

Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, then reach out to the study team directly at the contact information above and someone will assist you.

Your information will be shared only with the research study team and administrative staff for recruitment and will remain confidential. Your information will be stored until study recruitment is closed. Should you no longer want this information to be provided in the aforementioned ways, please contact the study team directly.

Study teams can login to review submissions
Study Team Login